OR WAIT null SECS
The company invested $50 million in an expansion at its Charles City, Iowa facility.
Cambrex Corporation announced on July 12, 2016 the completion and validation of a $50-million production and warehousing expansion at its cGMP Charles City, Iowa site. The new 7500-sq-ft. multi-purpose manufacturing facility will initially add a total of 70m3 of glass-lined and Hastelloy reactors ranging in size from 7m3 to 16m3, along with 6m2 Hastelloy agitated filter dryers to provide a flexible, multi-purpose configuration, and will be capable of handling potent APIs at an occupational exposure limit (OEL) of down to 1μg/m3. The facility complements the three existing large-scale manufacturing facilities at the Charles City site.
The 36,000-sq.-ft. cGMP warehouse provides general cGMP storage for 2720 pallets and segregated 2–8 °C refrigerated storage for 360 pallet spaces and features distributed control system monitoring, and control for temperature and humidity. The facility employs a barcode system for automated bin location and has a dedicated sampling room with appropriate extraction and handling for flammable materials. Additionally, a further 7500-sq.-ft. manufacturing shell has been constructed that will be fitted out to customer specification.
Cambrex’s Charles City, Iowa facility sits on a 45-acre site and manufactures a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. The facility is authorized by the United States Drug Enforcement Administration to import narcotic raw materials at commercial scale.
Source: Cambrex Corporation